A High Capacity Polymeric Micelle of Paclitaxel: Implication of High Dose Drug Therapy to Safety and in Vivo Anti-Cancer Activity
Zhijian He,Xiaomeng Wan,Anita Schulz,Herdis Bludau,Marina A. Dobrovolskaia,Stephan T. Stern,Stephanie A. Montgomery,Hong Yuan,Zibo Li,Dania Alakhova,Marina Sokolsky,David B. Darr,Charles M. Perou,Rainer Jordan,Robert Luxenhofer,Alexander V. Kabanov
DOI: https://doi.org/10.1016/j.biomaterials.2016.06.002
2016-01-01
Abstract:The poor solubility of paclitaxel (PTX), the commercially most successful anticancer drug, has long been hampering the development of suitable formulations. Here, we present translational evaluation of a nanoformulation of PTX, which is characterized by a facile preparation, extraordinary high drug loading of 50% wt. and PTX solubility of up to 45 g/L, excellent shelf stability and controllable, sub-100 nm size. We observe favorable in vitro and in vivo safety profiles and a higher maximum tolerated dose compared to clinically approved formulations. Pharmacokinetic analysis reveals that the higher dose administered leads to a higher exposure of the tumor to PTX. As a result, we observed improved therapeutic outcome in orthotopic tumor models including particularly faithful and aggressive “T11” mouse claudin-low breast cancer orthotopic, syngeneic transplants. The promising preclinical data on the presented PTX nanoformulation showcase the need to investigate new excipients and is a robust basis to translate into clinical trials.